

Rinani Group Berhad Acquires 5.85% Stake in Malaysian Genomics

Executive Chairman Azri Azerai Welcomes Rinani Group Berhad as Substantial Shareholder in Group's Restructuring

PETALING JAYA, 14 July 2023 – **Malaysian Genomics Resource Centre Berhad** ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, announces today that Rinani Group Berhad ("Rinani") has become a substantial shareholder by acquiring a 5.85% stake equivalent to 7.62 million shares in the Group.

Azri Azerai, the Group's Executive Chairman, welcomed this significant development, "We are excited to have Rinani Group Berhad on board as a substantial shareholder. Their investment comes at a pivotal time as we are transitioning towards biopharmaceuticals and pursuing various growth initiatives."

Azri emphasized that the addition of Rinani as a substantial shareholder would play a crucial role in the Group's restructuring and next phase of growth. "Their involvement brings a wealth of opportunities in life sciences and its applications, which aligns with our growth strategy," he said.

The Group's recent initiatives are underscored by a supply agreement between its wholly-owned subsidiary, MGRC Healthcare Sdn Bhd ("MGRC-H"), and DLF Engineering Pte Ltd ("DLF"). This agreement entails MGRC-H supplying DLF with genetic screening tests and cell products such as application-specific mesenchymal stem cells, NK cells, exosomes, and rejuvenium for a year, with potential renewal upon mutually agreed terms.

In conclusion, Azri said, "Rinani's arrival as a substantial shareholder strengthens our financial standing and our capacity to capitalise on burgeoning opportunities in the healthcare sector. Together, we are better positioned to deliver sustainable value to our stakeholders."

As of 15 July 2023, MGRC's share price stood at 0.455 sen, reflecting a market capitalisation of RM59.20 million.

###

ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group") is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

For more information, visit www.mgrc.com.my.

Issued By: Swan Consultancy Sdn. Bhd. on behalf of Malaysian Genomics Resource Centre Berhad

For more information, please contact:

Jazzmin Wan

Tel: +60 17-289 4110

Email: j.wan@swanconsultancy.biz

Amida Baharim

Tel: +60 12-206 1209

Email: a.baharim@swanconsultancy.biz
